Clinical pharmacokinetics of phenobarbital in neonates

被引:30
|
作者
Touw, DJ
Graafland, O
Cranendonk, A
Vermeulen, RJ
van Weissenbruch, MM
机构
[1] Free Univ Amsterdam, Med Ctr, Dept Pharm, NL-1081 HV Amsterdam, Netherlands
[2] Free Univ Amsterdam, Med Ctr, Dept Neonatol, NL-1081 HV Amsterdam, Netherlands
[3] Free Univ Amsterdam, Med Ctr, Dept Child Neurol, NL-1081 HV Amsterdam, Netherlands
关键词
phenobarbital; pharmacokinetics; neonate; gestational age;
D O I
10.1016/S0928-0987(00)00145-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Demographic and clinical pharmacokinetic data collected from term and preterm neonates who were treated with intravenous phenobarbital have been analysed to evaluate the role of patient characteristics in pharmacokinetic parameters. Significant relationships between total body weight (TBW) or body surface area (BSA) and volume of distribution (Vd) and total body clearance (CL) were found. Coefficients of determination were: 0.55 and 0.59 for Vd, and 0.76 and 0.72 for CL against TBW and BSA, respectively. In addition, significant relationships between height of the infants and volume of distribution of phenobarbital and total body clearance were observed. Coefficients of determination were 0.58 for Vd and 0.56 for CL. A weaker but significant correlation existed between gestational age and Vd or CL of phenobarbital. Coefficients of determination were 0.43 and 0.64, respectively. There was no correlation between volume of distribution per kg body weight or total body clearance per kg body weight and any patient parameter investigated. However, these latter pharmacokinetic parameters tended to decrease with increasing gestational age and height of the neonates. The results obtained were used to develop new loading and maintenance doses for phenobarbital in neonates based on total body weight and body surface area and based on height and gestational age for cases that weight is not available. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 50 条
  • [1] Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics
    Pacifici, Gian M.
    CURRENT PEDIATRIC REVIEWS, 2016, 12 (01) : 48 - 54
  • [2] Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation
    Pokorna, Pavla
    Sima, Martin
    Vobruba, Vaclav
    Tibboel, Dick
    Slanar, Ondrej
    PERFUSION-UK, 2018, 33 : 80 - 86
  • [3] What Is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?
    Sima, Martin
    Michalickova, Danica
    Slanar, Ondrej
    PHARMACEUTICS, 2021, 13 (03) : 1 - 15
  • [4] Clinical Pharmacology of Teicoplanin in Neonates: Effects and Pharmacokinetics
    Pacifici, Gian Maria
    INTERNATIONAL JOURNAL OF PEDIATRICS-MASHHAD, 2016, 4 (10): : 3669 - 3684
  • [5] Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions
    Kokwaro, GO
    Ogutu, BR
    Muchohi, SN
    Otieno, GO
    Newton, CRJC
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (04) : 453 - 457
  • [6] Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia
    Favie, Laurent M. A.
    Groenendaal, Floris
    van den Broek, Marcel P. H.
    Rademaker, Carin M. A.
    de Haan, Timo R.
    van Straaten, Henrica L. M.
    Dijk, Peter H.
    van Heijst, Arno
    Simons, Sinno H. P.
    Dijkman, Koen P.
    Rijken, Monique
    Zonnenberg, Inge A.
    Cools, Filip
    Zecic, Alexandra
    van der Lee, Johanna H.
    Nuytemans, Debbie H. G. M.
    van Bel, Frank
    Egberts, Toine C. G.
    Huitema, Alwin D. R.
    Brouwer, Mieke J.
    Mulder-de Tollenaer, S. M.
    Jebbink-Akkerman, L. J. M. Groot
    Liem, Djien
    Steiner, Katerina
    Dudink, Jeroen
    de Jonge, Rogier C. J.
    Bos, Annelies A.
    Sonnaert, Michel
    Camfferman, Fleur Anne
    NEONATOLOGY, 2019, 116 (02) : 154 - 162
  • [7] Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update
    Yukawa, M.
    Yukawa, E.
    Suematsu, F.
    Takiguchi, T.
    Ikeda, H.
    Aki, H.
    Mimemoto, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (06) : 704 - 710
  • [8] Pharmacokinetic characteristics of phenobarbital in hyperbilirubinemic neonates
    Munoz, A
    Uberos, J
    Molina, A
    Gomez, A
    Valenzuela, A
    Narbona, E
    Molina-Font, JA
    PRENATAL AND NEONATAL MEDICINE, 1998, 3 (04): : 410 - 416
  • [9] Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach
    Marsot, Amelie
    Brevaut-Malaty, Veronique
    Vialet, Renaud
    Boulamery, Audrey
    Bruguerolle, Bernard
    Simon, Nicolas
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 (04) : 465 - 471
  • [10] Clinical Pharmacology of Meropenem in Neonates: Effects and Pharmacokinetics
    Pacifici, Gian Maria
    INTERNATIONAL JOURNAL OF PEDIATRICS-MASHHAD, 2016, 4 (11): : 3925 - 3939